

# Stuart McPherson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5094945/publications.pdf>

Version: 2024-02-01

110  
papers

5,965  
citations

159585

30  
h-index

74163

75  
g-index

113  
all docs

113  
docs citations

113  
times ranked

7689  
citing authors

#	ARTICLE	IF	CITATIONS
1	Physical Activity, Inactivity and Sleep in Patients with Significant Non-Alcoholic Fatty Liver Disease. American Journal of the Medical Sciences, 2022, 363, 80-83.	1.1	0
2	Viral hepatitis in 2021: The challenges remaining and how we should tackle them. World Journal of Gastroenterology, 2022, 28, 76-95.	3.3	15
3	Identification of liver disease: why and how. Frontline Gastroenterology, 2022, 13, 367-373.	1.8	12
4	Improved outcomes following the implementation of a decompensated cirrhosis discharge bundle. Frontline Gastroenterology, 2022, 13, 409-415.	1.8	7
5	Systematic review and meta-analysis: Associations between metabolic syndrome and colorectal neoplasia outcomes. Colorectal Disease, 2022, 24, 681-694.	1.4	5
6	Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (<scp>NAFLD</scp>). Alimentary Pharmacology and Therapeutics, 2022, 55, 1441-1451.	3.7	9
7	COVID-19 and liver cancer: lost patients and larger tumours. BMJ Open Gastroenterology, 2022, 9, e000794.	2.7	19
8	Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group. The Lancet Gastroenterology and Hepatology, 2022, 7, 755-769.	8.1	34
9	Community pathways for the early detection and risk stratification of chronic liver disease: a narrative systematic review. The Lancet Gastroenterology and Hepatology, 2022, 7, 770-780.	8.1	12
10	Letter: non-invasive prediction models to exclude cirrhosis in <scp>NAFLD</scp> â€” not everyone fits the mould. Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 56, 182-183.	3.7	0
11	Final safety and efficacy results from a 106 real-world patients registry with an ascitesâ€mobilizing pump. Liver International, 2022, 42, 2247-2259.	3.9	4
12	Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection. Journal of Viral Hepatitis, 2021, 28, 168-176.	2.0	7
13	Persistent Hepatitis E virus infection across England and Wales 2009â€2017: Demography, virology and outcomes. Journal of Viral Hepatitis, 2021, 28, 420-430.	2.0	12
14	Progress towards micro-elimination of hepatitis C in the custodial setting. Journal of Viral Hepatitis, 2021, 28, 300-301.	2.0	4
15	Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease. Frontline Gastroenterology, 2021, 12, 578-585.	1.8	17
16	The pathway to better primary care for chronic liver disease. British Journal of General Practice, 2021, 71, 180-182.	1.4	3
17	Association of exercise participation levels with cardiometabolic health and quality of life in individuals with hepatitis C. BMJ Open Gastroenterology, 2021, 8, e000591.	2.7	0
18	Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C. Wellcome Open Research, 2021, 6, 93.	1.8	1

#	ARTICLE	IF	CITATIONS
19	Nutrigenetics-based intervention approach for adults with non-alcoholic fatty liver disease (NAFLD): study protocol for a randomised controlled feasibility trial. <i>BMJ Open</i> , 2021, 11, e045922.	1.9	1
20	Uncovering undiagnosed liver disease: prevalence and opportunity for intervention in a population attending colonoscopy. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000638.	2.7	7
21	Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C. <i>Wellcome Open Research</i> , 2021, 6, 93.	1.8	7
22	Factors associated with engagement and adherence to a low-energy diet to promote 10% weight loss in patients with clinically significant non-alcoholic fatty liver disease. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000678.	2.7	6
23	Embedding assessment of liver fibrosis into routine diabetic review in primary care. <i>JHEP Reports</i> , 2021, 3, 100293.	4.9	23
24	Digital Intervention With Lifestyle Coach Support to Target Dietary and Physical Activity Behaviors of Adults With Nonalcoholic Fatty Liver Disease: Systematic Development Process of VITALISE Using Intervention Mapping. <i>Journal of Medical Internet Research</i> , 2021, 23, e20491.	4.3	12
25	HCV Activates Somatic L1 Retrotransposition—A Potential Hepatocarcinogenesis Pathway. <i>Cancers</i> , 2021, 13, 5079.	3.7	7
26	Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT. <i>Efficacy and Mechanism Evaluation</i> , 2021, 8, 1-90.	0.7	0
27	Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liver disease: a qualitative study. <i>Translational Behavioral Medicine</i> , 2020, 10, 1016-1030.	2.4	34
28	High rate of hepatitis C reinfection following antiviral treatment in the North East England Prisons. <i>Journal of Viral Hepatitis</i> , 2020, 27, 449-452.	2.0	21
29	Feasibility of a Very Low Calorie Diet to Achieve a Sustainable 10% Weight Loss in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00231.	2.5	28
30	Increased cardiovascular risk and reduced quality of life are highly prevalent among individuals with hepatitis C. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000470.	2.7	9
31	A transcriptomic signature predicting fibrosis progression in a large European cohort of patients with histologically characterised NAFLD. <i>Journal of Hepatology</i> , 2020, 73, S109-S110.	3.7	0
32	Pre-formed donor specific antibodies and aetiology of liver disease are associated with increased incidence of acute cellular rejections after liver transplantation. <i>Journal of Hepatology</i> , 2020, 73, S275.	3.7	0
33	Diet lifestyle management of non-alcoholic fatty liver disease (NAFLD): a cross-sectional survey of clinicians. <i>Journal of Hepatology</i> , 2020, 73, S562-S563.	3.7	0
34	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020, 158, 1611-1625.e12.	1.3	575
35	Clinical performance of Determine HBsAg 2 rapid test for Hepatitis B detection. <i>Journal of Medical Virology</i> , 2020, 92, 3403-3411.	5.0	14
36	Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI $\geq 1$ in a Single-Arm, Open-Label, Multicenter Study. <i>Advances in Therapy</i> , 2019, 36, 3458-3470.	2.9	7

#	ARTICLE	IF	CITATIONS
37	Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2019, 1, 188-198.	4.9	86
38	Convalescent plasma therapy for persistent hepatitis E virus infection. <i>Journal of Hepatology</i> , 2019, 71, 434-438.	3.7	17
39	The degree of hepatic steatosis associates with impaired cardiac and autonomic function. <i>Journal of Hepatology</i> , 2019, 70, 1203-1213.	3.7	45
40	Barriers and Facilitators to Mediterranean Diet Adoption by Patients With Nonalcoholic Fatty Liver Disease in Northern Europe. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1364-1371.e3.	4.4	42
41	Distance to treatment as a factor for loss to follow up of hepatitis C patients in North East England. <i>Journal of Public Health</i> , 2019, 41, 700-706.	1.8	12
42	Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy. <i>Journal of Viral Hepatitis</i> , 2019, 26, 231-235.	2.0	20
43	Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine. <i>Journal of Viral Hepatitis</i> , 2019, 26, 101-108.	2.0	57
44	Management of decompensated cirrhosis. <i>Clinical Medicine</i> , 2018, 18, s60-s65.	1.9	52
45	Editorial: NAFLD in Asia—clinical associations with advanced disease become clearer. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1035-1036.	3.7	1
46	A Placebo-Controlled, Multicenter, Double-Blind, Phase 2 Randomized Trial of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely Decompensated Cirrhosis. <i>Journal of Clinical and Experimental Hepatology</i> , 2018, 8, 224-234.	0.9	32
47	Summary of the British Transplantation Society UK Guidelines for Hepatitis E and Solid Organ Transplantation. <i>Transplantation</i> , 2018, 102, 15-20.	1.0	58
48	Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. <i>Gut</i> , 2017, 66, 1321-1328.	12.1	172
49	Editorial: further evidence for the use of advanced magnetic resonance imaging techniques to monitor <sc>NAFLD</sc>. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1269-1270.	3.7	2
50	Effects of Exercise on Liver Fat and Metabolism in Alcohol Drinkers. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1596-1603.e3.	4.4	9
51	Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. <i>Frontline Gastroenterology</i> , 2017, 8, 252-259.	1.8	22
52	Lifestyle Behavior Change in Patients With Nonalcoholic Fatty Liver Disease: A Qualitative Study of Clinical Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1968-1971.	4.4	37
53	Editorial: progress towards a simple tool for screening for hepatic steatosis in the general population. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 559-560.	3.7	1
54	Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 981-991.	3.7	46

#	ARTICLE	IF	CITATIONS
55	Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies. <i>Journal of Hepatology</i> , 2017, 66, S593.	3.7	7
56	Simple non-invasive fibrosis scores identify patients with non-alcoholic fatty liver disease who progress to advanced fibrosis/cirrhosis:evidence from a large cohort of patients with sequential liver biopsies. <i>Journal of Hepatology</i> , 2017, 66, S68-S69.	3.7	0
57	Editorial: improving inâ€hospital management of decompensated cirrhosis by a â€care bundleâ€™ â€ hope, frustration and lessons to learn. Authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 755-756.	3.7	1
58	Exercise Reduces Liver Lipids and Visceral Adiposity in Patientsâ€With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 96-102.e3.	4.4	163
59	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , 2017, 112, 740-751.	0.4	524
60	Imaging-Based Assessment of Steatosis, Inflammation and Fibrosis in NAFLD. <i>Current Hepatology Reports</i> , 2017, 16, 298-307.	0.9	9
61	A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. <i>PLoS ONE</i> , 2017, 12, e0175717.	2.5	46
62	PTU-093â€...An Audit of Primary Prophylaxis Against Variceal Bleeding Amongst Patients with Cirrhosis. <i>Gut</i> , 2016, 65, A100.3-A101.	12.1	0
63	PTH-107â€...Chronic Hepatitis B Management The UK: A National Survey of Current Practice Following Nice Guidance. <i>Gut</i> , 2016, 65, A271.2-A272.	12.1	0
64	PTH-115â€...Increasing Access to Hepatitis C Treatment in The North East of England. <i>Gut</i> , 2016, 65, A275-A276.	12.1	0
65	Implementation of a â€care bundleâ€™ improves the management of patients admitted to hospital with decompensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 1030-1038.	3.7	30
66	Changing epidemiology of chronic liver disease among ethnic groups in the United States. <i>Hepatology</i> , 2016, 64, 1843-1846.	7.3	3
67	Improving testing for hepatitis B before treatment with rituximab. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1172-1178.	1.6	16
68	Reply to â€Liver failure in human immunodeficiency virus â€ Hepatitis C virus coinfection treated with sofosbuvir, ledipasvir and antiretroviral therapyâ€. <i>Journal of Hepatology</i> , 2016, 64, 753-754.	3.7	4
69	Imagestream detection and characterisation of circulating tumour cells â€ A liquid biopsy for hepatocellular carcinoma?. <i>Journal of Hepatology</i> , 2016, 65, 305-313.	3.7	98
70	Response to the NCEPOD report: development of a care bundle for patients admitted with decompensated cirrhosisâ€the first 24â€...h. <i>Frontline Gastroenterology</i> , 2016, 7, 16-23.	1.8	36
71	Decompensated alcohol related liver disease: acute management. <i>BMJ, The</i> , 2016, 352, i124.	6.0	32
72	Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. <i>Journal of Hepatology</i> , 2016, 64, 234-238.	3.7	85

#	ARTICLE	IF	CITATIONS
73	Hepatitis C in a prison in the North East of England: what is the economic impact of the universal offer of testing and emergent medications?. <i>Journal of Public Health</i> , 2015, 38, fdv178.	1.8	2
74	PWE-120 High rate of false positives for advanced fibrosis when simple non-invasive fibrosis tests are used in older patients (≥ 65 years) with nafld. <i>Gut</i> , 2015, 64, A265.1-A265.	12.1	0
75	Republished: Non-alcoholic fatty liver disease: a practical approach to treatment. <i>Postgraduate Medical Journal</i> , 2015, 91, 92-101.	1.8	20
76	Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. <i>Journal of Hepatology</i> , 2015, 62, 1148-1155.	3.7	840
77	Hepatitis B in pregnancy. <i>Frontline Gastroenterology</i> , 2014, 5, 111-117.	1.8	14
78	Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. <i>Frontline Gastroenterology</i> , 2014, 5, 211-218.	1.8	254
79	Lesson of the month 2: Severe reactivation of hepatitis B after immunosuppressive chemotherapy. <i>Clinical Medicine</i> , 2014, 14, 551-555.	1.9	6
80	Non-alcoholic fatty liver disease: a practical approach to treatment. <i>Frontline Gastroenterology</i> , 2014, 5, 277-286.	1.8	90
81	Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2014, 60, 1055-1062.	3.7	85
82	Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. <i>Postgraduate Medical Journal</i> , 2014, 90, 254-266.	1.8	12
83	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. <i>Nature Communications</i> , 2014, 5, 4309.	12.8	478
84	PTH-090 Natural History Of Nafld: A Study Of 108 Patients With Paired Liver Biopsies. <i>Gut</i> , 2014, 63, A249.2-A250.	12.1	0
85	Improving access to treatment for patients with chronic hepatitis C through outreach. <i>Frontline Gastroenterology</i> , 2013, 4, 125-129.	1.8	5
86	Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. <i>Journal of Clinical Pathology</i> , 2013, 66, 1033-1045.	2.0	70
87	Targeted case finding for hepatitis B using dry blood spot testing in the British Chinese and South Asian populations of the North East of England. <i>Journal of Viral Hepatitis</i> , 2013, 20, 638-644.	2.0	28
88	Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 652-658.	1.6	76
89	Cholestasis secondary to anabolic steroid use in young men. <i>BMJ: British Medical Journal</i> , 2012, 344, e468-e468.	2.3	29
90	PMO-171 A pilot of targeted case finding for hepatitis B virus (HBV) and hepatitis C (HCV) in the British South Asian community. <i>Gut</i> , 2012, 61, A143.1-A143.	12.1	1

#	ARTICLE	IF	CITATIONS
91	How big a problem is non-alcoholic fatty liver disease?. BMJ: British Medical Journal, 2011, 343, d3897-d3897.	2.3	161
92	P54 CHASE-B (Chinese Hepatitis Awareness, Surveillance and Education): a pilot of targeted case finding for hepatitis B virus (HBV) in the British-Chinese community. Gut, 2011, 60, A25-A26.	12.1	2
93	P81 Pre-transplant histological assessment in patients with alcoholic liver disease does not predict risk of recidivism post liver transplantation. Gut, 2011, 60, A37-A38.	12.1	0
94	OP11 Are simple non-invasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?. Gut, 2011, 60, A54-A55.	12.1	0
95	Undiagnosed chronic hepatitis B is prevalent in the british-chinese community of the north east (NE) of england. Gut, 2011, 60, A241-A241.	12.1	2
96	No evidence of the unfolded protein response in patients with chronic hepatitis C virus infection. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 319-327.	2.8	16
97	OC-017...A comparison of non-invasive fibrosis scoring systems in patients with non-alcoholic fatty liver disease: Abstract OC-017. Gut, 2010, 59, A7.2-A8.	12.1	0
98	Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut, 2010, 59, 1265-1269.	12.1	690
99	Results of a Two-Center Study Comparing Hepatic Fibrosis Progression in HCV-positive Liver Transplant Patients Receiving Cyclosporine or Tacrolimus. Transplantation Proceedings, 2010, 42, 4573-4577.	0.6	9
100	Combined approach for non-invasive measurement of liver pathology by MR. Journal of Hepatology, 2009, 51, 1083-1084.	3.7	1
101	Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered. Journal of Hepatology, 2009, 51, 389-397.	3.7	156
102	Investigation of the role of SREBP-1c in the pathogenesis of HCV-related steatosis. Journal of Hepatology, 2008, 49, 1046-1054.	3.7	46
103	An alcoholic patient who continues to drink: case progression. BMJ: British Medical Journal, 2006, 332, 98.	2.3	0
104	An alcoholic patient who continues to drink: case presentation. BMJ: British Medical Journal, 2006, 332, 33.	2.3	1
105	Intravenous Immunoglobulin for the Treatment of Severe, Refractory, and Recurrent Clostridium difficile Diarrhea. Diseases of the Colon and Rectum, 2006, 49, 640-645.	1.3	179
106	An alcoholic patient who continues to drink: case outcome. BMJ: British Medical Journal, 2006, 332, 276.	2.3	5
107	Postoperative methicillin-resistant Staphylococcus aureus enteritis following hysterectomy: a case report and review of the literature. European Journal of Gastroenterology and Hepatology, 2005, 17, 1225-1227.	1.6	5
108	Acute hepatitis C in a nursing home resident. Age and Ageing, 2005, 34, 188-189.	1.6	0

#	ARTICLE	IF	CITATIONS
109	001.â€fFalse-Positive Hepatitis B Serology Due to Suspected Cross-Reactivity in a Patient with Rheumatoid Arthritis. <i>Rheumatology</i> , 0, , .	1.9	3
110	Determining the frequency and characteristics of Hepatitis C reinfections in North East England. <i>Journal of Viral Hepatitis</i> , 0, , .	2.0	2